Incyte — Drug Prices & Medicare Spending
Incyte manufactures 3 drugs tracked by Medicare Part D with total spending of $3.1B.
3
Drugs Tracked
$3.1B
Medicare Spending
$3,527.71
Avg Cost/Claim
67%
Have Generics
Incyte Drugs — Ranked by Medicare Spending
| # | Drug | Generic Name | Cost/Claim | Generic? |
|---|---|---|---|---|
| 1 | Jakafi | Ruxolitinib | $11,432.00 | No |
| 2 | Opzelura | Ruxolitinib (topical) | $375.00 | Yes |
| 3 | Pemazyre | Pemigatinib | $20,500.00 | Yes |
Frequently Asked Questions
Incyte manufactures 3 drugs tracked by Medicare Part D, with total annual spending of $3.1B.
Pemazyre (Pemigatinib) is the most expensive at $20,500.00 per claim.
2 of 3 Incyte drugs (67%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.